2 treatment centers
No centers match
Try a different search term
2 SAMHSA-listed treatment centers in Arlington, Texas. Free, confidential help available 24/7 — most callers reach a licensed counselor in under 60 seconds.
Try a different search term
Arlington, Texas has 2 SAMHSA-verified addiction treatment centers offering a range of evidence-based programs. Texas is a major transit corridor for illicit drugs, with rising fentanyl and heroin deaths across the state.
Available programs in Arlington include, 2 outpatient programs, 2 dual diagnosis (co-occurring mental health) programs. All listed facilities are sourced directly from the federal SAMHSA National Registry of Substance Abuse Treatment Services.
Most treatment centers in Arlington accept Medicaid, Medicare, and major private insurance plans including Aetna, Cigna, BlueCross BlueShield, and UnitedHealthcare. Under the Affordable Care Act (ACA) and the Mental Health Parity Act, insurance providers are required to cover substance use disorder treatment at the same level as other medical conditions. Call (319) 271-2077 for a free insurance verification — no obligation, completely confidential.
When selecting from the 2 treatment options in Arlington, consider: the type and severity of the substance use disorder, whether co-occurring mental health conditions require dual diagnosis treatment, your insurance coverage and financial situation, the distance from home and your support network, and the facility's accreditation and evidence-based approach. Our helpline is available 24/7 at (319) 271-2077 to help match you with the right program — free and confidential.
Free, confidential assistance matching you with the right program in Arlington.
Treatment centers in Arlington accept most major insurance plans including Medicaid, Medicare, Blue Cross Blue Shield, Aetna, Cigna, and UnitedHealthcare. Many facilities also offer sliding scale fees and payment plans. Call (319) 271-2077 to verify your coverage before admission.
Anxiety disorders complicate addiction recovery for many Arlington patients, particularly in early recovery when anxiety symptoms often intensify without the substance previously used to suppress them. Treatment approaches include cognitive-behavioral therapy specifically for anxiety, judicious psychiatric medication management (avoiding benzodiazepines for most patients in addiction recovery given the dependence risk), structured exposure work, mindfulness-based interventions, and lifestyle interventions (sleep, exercise, caffeine moderation) that compound the formal treatment effects.
Documentation and consent at Arlington program admission is structured to comply with 42 CFR Part 2 confidentiality of substance-use treatment records — a heightened standard above HIPAA. Patients typically sign multiple consent forms: treatment consent, releases for specific communications (with family, employer, legal contacts, other providers), and acknowledgments of program policies. These consents are revocable and patients retain control over disclosure of their treatment information except for narrow regulatory exceptions.
Relapse is statistically common in addiction recovery and does not signal treatment failure for Arlington patients. National data shows roughly 40-60% of patients experience at least one relapse within the first year post-treatment, paralleling chronic-disease relapse rates (hypertension, asthma, diabetes). Treatment models increasingly frame addiction as a chronic condition requiring long-term management rather than acute episodes with cures. Relapse response should be immediate re-engagement with treatment, not discharge from the recovery community.
Patients searching for treatment in Arlington often face decision fatigue: dozens of facilities advertise similar services, success-rate claims are unverifiable, and insurance-coverage details are opaque until the verification call. The pragmatic approach is to screen along a few specific criteria — licensing status, accepted insurance, ASAM-aligned clinical assessment, dual-diagnosis capacity, family involvement, and aftercare planning — rather than to rely on marketing claims or reviews. Each of the Arlington providers listed has been screened against these criteria before inclusion.
Medicaid coverage for addiction treatment in Arlington depends on Texas's Medicaid program structure, expansion status, and any 1115 waivers in effect. The federal IMD Exclusion historically limited Medicaid coverage of large residential facilities; many states have obtained 1115 waivers expanding this coverage. Patients with Medicaid in Texas should contact their managed-care plan or the state Medicaid office to identify in-network addiction-treatment providers — many residential facilities accept Medicaid even when their primary patient mix is commercial.
Withdrawal severity is the first clinical screening factor for treatment entry in Arlington. Patients showing or at risk for moderate-to-severe alcohol or benzodiazepine withdrawal typically require medically managed detox before transitioning to lower-intensity care — untreated severe alcohol withdrawal carries 5% mortality and severe benzodiazepine withdrawal can be fatal. Opioid use patients face a different pathway: detox-only is rarely effective for opioid use disorder, and evidence-based protocols typically initiate medication-assisted treatment (buprenorphine or methadone) during the stabilization phase.
Withdrawal from alcohol or benzodiazepines can be medically dangerous and should not be attempted at home by Arlington residents with daily or heavy use. Signs of severe withdrawal requiring emergency care include seizures, hallucinations, severe tremor, disorientation, fever, and autonomic instability. Delirium tremens (DTs) carries 5% mortality without treatment and occurs in 3-5% of heavy alcohol users withdrawing. Medical detox at a licensed Arlington facility is the standard of care for these presentations.